Form 8-K/A - Current report: [Amend]
SEC Accession No. 0001723128-24-000044
Filing Date
2024-11-12
Accepted
2024-11-12 16:25:55
Documents
15
Period of Report
2024-11-08
Items
Item 2.02: Results of Operations and Financial Condition
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K/A amrx-20241108.htm   iXBRL 8-K/A 31246
2 EX-99.1 amrx-q32024ex991.htm EX-99.1 503624
6 amneal.jpg GRAPHIC 2670
  Complete submission text file 0001723128-24-000044.txt   704819

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT amrx-20241108.xsd EX-101.SCH 1876
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT amrx-20241108_lab.xml EX-101.LAB 22742
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT amrx-20241108_pre.xml EX-101.PRE 13122
18 EXTRACTED XBRL INSTANCE DOCUMENT amrx-20241108_htm.xml XML 3157
Mailing Address 400 CROSSING BOULEVARD 3RD FLOOR BRIDGEWATER NJ 08807
Business Address (908) 947-3120
Amneal Pharmaceuticals, Inc. (Filer) CIK: 0001723128 (see all company filings)

EIN.: 000000000 | Fiscal Year End: 1231
Type: 8-K/A | Act: 34 | File No.: 001-38485 | Film No.: 241448715
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)